Retifanlimab shows promising antitumor activity in advanced endometrial cancer
Retifanlimab demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high or mismatch repair deficient endometrial cancer, according to data from the phase 1 POD1UM-101 trial.
CoopERA Results Show Benefits of Giredestrant in ER+/HER2– Early Breast Cancer
Sara Hurvitz, MD, discusses the coopERA study and how these data, along with findings from other clinical trials, could lead to significant changes in treatment for patients with ER-positive/HER2-negative breast cancer.
KEYNOTE-826 data in cervical cancer and next steps for research
Bradley J. Monk, MD, FACS, FACOG, discusses the practice-changing data from KEYNOTE-826 examining pembrolizumab plus chemotherapy with or without bevacizumab and next steps for research in recurrent or metastatic cervical cancer.
2 Commerce Drive Cranbury, NJ 08512